MISSISSAUGA, ON–(Marketwired – May 03, 2017) – MedX Health Corp. (“MedX” or the “Company”) (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Paul Cohen, a board certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada, to its Medical/Scientific Advisory Board. Dr. Cohen is also a diplomat of the American Board of Dermatology and is a member of numerous associations, including the Canadian Dermatological Association and the Toronto Dermatological Society.
“Paul is a highly respected physician renowned across North America for his exceptional work as a dermatologist. He is a leader in the field of dermatological medicine and we are honored to have him join MedX’s Medical/Scientific Advisory Board,” said Robert von der Porten, CEO of MedX. “Paul was an early adopter of our SIAscopy technology, and he has seen first-hand the positive impact our technology has on people’s lives. Having Paul as a member of our Advisory Board is meaningful, and we believe his insights will help us achieve MedX’s goal of being an international player in the skin cancer diagnostics sector,” Mr. von der Porten added.
“The value of MedX’s innovative technology that helps save lives is undeniable. Skin cancer rates are rising expeditiously around the world, and in some areas of the globe it’s bordering on epidemic levels. If the medical community had access to MedX’s SIAscopy technology — that would be a game-changer and could save many millions of lives,” Dr. Cohen said.
Dr. Cohen has been using MedX’s SIAscopy screening technology in his practice at Rosedale Dermatology Centre in Toronto since 2016, and has also provided patient skin assessments for some of MedX’s pilot projects. “MedX’s SIAscopy technology allows me to make more confident assessments of my telemedicine patients. The technology not only provides me with a dermascopic view, but also provides four additional views of potential critical markers 2 mm below the skin’s surface. It allows me to mark exactly where on the body the image was taken and, if in six months I re-scan the same suspicious mole or lesion, I can directly and more accurately compare that image with the original image and document any changes. MedX’s technology fits perfectly in my workflow and allows me to see more patients without compromising quality care,” Dr. Cohen noted.
Dr. Cohen graduated from the University of Toronto Medical School in 1995, and completed his dermatology residence in 2001. He was awarded the Ben Fisher Galderma fellowship in clinical dermatology where he completed additional training in cosmetic, surgical and pediatric dermatology.
Dr. Cohen provides regular dermatology-related commentary to a wide variety of media, including CTV, Global and CBC news outlets.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. SIAscopy products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a specialized product used in a unique market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non- invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.
Contacts:
Rob von der Porten
President & CEO
MedX Health Corp
905-670-4428 ext 226
Media Relations
Deborah Thompson
[email protected]
416-918-9551
